-
公开(公告)号：US20210169921A1
公开(公告)日：2021-06-10
申请号：US16941935
申请日：2020-07-29
发明人： Susan M. Freier , Chenguang Zhao , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Andrew M. Siwkowski
IPC分类号： A61K31/7125 , C07H21/00 , C12N15/113 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/737 , A61K31/727
摘要： Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
-
公开(公告)号：US20170035798A1
公开(公告)日：2017-02-09
申请号：US15075545
申请日：2016-03-21
发明人： Susan M. Freier , Chenguang Zhao , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Andrew M. Siwkowski
IPC分类号： A61K31/7125 , C12N15/113 , A61K31/4545 , A61K31/727 , A61K31/366
CPC分类号： A61K31/7125 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/727 , A61K31/737 , C07H21/00 , C12N15/1137 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12Y304/21027
摘要： Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
摘要翻译： 本文公开了用于减少因子11并在需要其的个体中治疗或预防血栓栓塞并发症的反义化合物和方法。 通过施用靶向因子11的反义化合物可以改善的疾病状况的实例包括血栓形成，栓塞和血栓栓塞，例如深静脉血栓形成，肺栓塞，心肌梗塞和中风。 靶向因子11的反义化合物也可用作预防性治疗，以预防患有血栓形成和栓塞风险的个体。
-
公开(公告)号：US20240327838A1
公开(公告)日：2024-10-03
申请号：US18492683
申请日：2023-10-23
IPC分类号： C12N15/113 , A61K9/00 , A61K31/404 , A61K31/47 , A61K31/7105 , A61K31/713 , A61M11/00 , A61P11/00
CPC分类号： C12N15/113 , A61K9/0019 , A61K9/0075 , A61K9/0078 , A61K31/404 , A61K31/47 , A61K31/7105 , A61K31/713 , A61P11/00 , A61M11/005 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/3341 , C12N2310/341 , C12N2310/345 , C12N2310/346 , C12N2320/31 , C12N2320/32 , C12N2320/35
摘要： The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
-
公开(公告)号：US20210180057A1
公开(公告)日：2021-06-17
申请号：US16759908
申请日：2018-10-31
IPC分类号： C12N15/113 , A61K9/00 , A61P11/00 , A61K31/404 , A61K31/47 , A61K31/7105 , A61K31/713
摘要： The present embodiments provide methods, compounds, and compositions useful for inhibiting ENaC expression, which may be useful for treating, preventing, or ameliorating a disease associated with ENaC.
-
公开(公告)号：US20190077825A1
公开(公告)日：2019-03-14
申请号：US16085130
申请日：2017-03-16
发明人： Richard Lee , Jeffrey R. Crosby
摘要： Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or condition related to oxidative stress an animal in need. Diseases, disorders or conditions related to oxidative stress include NASH, NAFLD, asthma and insulin resistance.
-
公开(公告)号：US20240294920A1
公开(公告)日：2024-09-05
申请号：US18569084
申请日：2022-06-30
发明人： Jeffrey R. Crosby , Chenguang Zhao , Alexey Revenko , Shuling Guo
IPC分类号： C12N15/113 , A61P11/00
CPC分类号： C12N15/1137 , A61P11/00 , C12Y106/03001 , C12N2310/11 , C12N2310/14 , C12N2310/316 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/3341 , C12N2320/32
摘要： Provided herein are methods, antisense agents, specific inhibitors, and compositions useful for reducing expression or activity of NADPH oxidase 4 (hereinafter referred to as NOX4) in a subject. Also, provided herein are methods, antisense agents, specific inhibitors, and compositions that can be useful in treating NOX4-related diseases or conditions in a subject. Such methods, antisense agents, specific inhibitors, and compositions can be useful, for example, to treat a pulmonary disease in a subject.
-
公开(公告)号：US20230002771A1
公开(公告)日：2023-01-05
申请号：US17554920
申请日：2021-12-17
IPC分类号： C12N15/113
摘要： Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXII RNA in a cell or subject, and in certain instances reducing the amount of FXII protein in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of a thromboembolic condition. Such thromboembolic conditions include deep vein thrombosis, venous or arterial thrombosis, pulmonary embolism, myocardial infarction, and stroke. Such symptoms include pain, shortness of breath, heart burn, cold sweat, fatigue, lightheadedness, dizziness, swelling, cramping, and death. Such compounds, methods, and pharmaceutical compositions are useful to prevent, treat, or ameliorate at least one symptom of hereditary angioedema.
-
公开(公告)号：US20220290137A1
公开(公告)日：2022-09-15
申请号：US17508516
申请日：2021-10-22
发明人： Susan M. Freier , Huynh-Hoa Bui , Shuling Guo , Jeffrey R. Crosby
IPC分类号： C12N15/113 , C07H21/04 , A61K9/00 , A61P11/00 , A61K47/02
摘要： Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a disease or condition characterized by excessive mucus production or fibrosis, including cystic fibrosis, asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), chronic bronchitis, rhinitis and ulcerative colitis.
-
公开(公告)号：US10961271B2
公开(公告)日：2021-03-30
申请号：US16085130
申请日：2017-03-16
发明人： Richard Lee , Jeffrey R. Crosby
IPC分类号： C07H21/02 , A61K31/7125 , A61K31/7115 , A61K31/713 , A61K31/712 , C07H21/04 , C12N15/113 , A61P9/10 , A61P25/28 , A61P11/06 , A61P3/10 , A61P29/00
摘要： Provided herein are methods, compounds, and compositions for reducing expression of KEAP1 in animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate oxidative stress or a disease, disorder or condition related to oxidative stress an animal in need. Diseases, disorders or conditions related to oxidative stress include NASH, NAFLD, asthma and insulin resistance.
-
公开(公告)号：US20230263822A1
公开(公告)日：2023-08-24
申请号：US18150381
申请日：2023-01-05
发明人： Susan M. Freier , Chenguang Zhao , Brett P. Monia , Hong Zhang , Jeffrey R. Crosby , Andrew M. Siwkowski
IPC分类号： A61K31/7125 , C07H21/00 , C12N15/113 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/737 , A61K31/727
CPC分类号： A61K31/7125 , C07H21/00 , C12Y304/21027 , C12N15/1137 , A61K31/366 , A61K31/4365 , A61K31/4545 , A61K31/713 , A61K31/737 , A61K31/727 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3341 , C12N2310/341 , C12N2310/346
摘要： Disclosed herein are antisense compounds and methods for decreasing Factor 11 and treating or preventing thromboembolic complications in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to Factor 11 include thrombosis, embolism, and thromboembolism, such as, deep vein thrombosis, pulmonary embolism, myocardial infarction, and stroke. Antisense compounds targeting Factor 11 can also be used as a prophylactic treatment to prevent individuals at risk for thrombosis and embolism.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.02 秒)
